Sickle Cell Disease Treatment Gets Panel Nod Despite Efficacy Concerns
US FDA's Oncologic Drugs Advisory Committee votes 10-3 in favor of approving Emmaus' L- glutamine, touting its strong safety profile and the unmet clinical need in spite of agency's questions about efficacy results.
You may also be interested in...
Epidiolex May Have Avoided CRL Over Metabolite Assessment Due To Unmet Need
Lead pharmacology/toxicology reviewer said Epdiolex was not approvable because of inadequate assessment of 7-COOH-CBD human metabolite, but supervisor said it could be conducted in postmarketing phase because of the unmet need the drug fills.
Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
The latest drug development news and highlights from our FDA Performance Tracker.
Unmet Need Can Trump Anything At US FDA Panels, Even An Ill-Prepared Sponsor
Emmaus was unable to answer several questions about its product and was also missing several pieces of data, but FDA's Oncologic Drugs Advisory Committee didn't criticize the sponsor, and instead praised it for paying attention to the largely neglected sickle cell disease.